Document is current
Any future updates will be listed below
-
Authors
Dres, Martin http://orcid.org/0000-0001-9191-6089
Rozenberg, Emmanuel
Morawiec, Elise
Mayaux, Julien
Delemazure, Julie
Similowski, Thomas
Demoule, Alexandre
-
Funding
Funding for this research was provided by:
Société de Réanimation de Langue Française
Société de Pneumologie de Langue Française
- License Information
-
More Information
Article History
Received: 6 March 2021
Accepted: 9 June 2021
First Online: 28 June 2021
Declarations
:
: The study was approved by the Comité de Protection des Personnes du Sud Ouest et Outre Mer 4 (RCB ID: 2018-A00176-49).
: Written and oral information about the study was given to patients or their families prior to enrolment. Informed consent was obtained from all patients or their relatives.
: Martin Dres received fees from Lungpacer (expertise, lectures). Thomas Similowski reports personal fees from AstraZeneca, Boehringer Ingelheim France, GSK, Novartis, Lungpacer Inc., TEVA, Chiesi, and Invacare. In addition, Dr. Similowski has a patent titled "brain-ventilator interface" licensed to Air Liquide Medical Systems and MyBrainTechnology, a patent for a "protection device for intubation" pending, and a patent for a "non-contact thoracic movement imaging system» pending. Alexandre Demoule reports personal fees from Medtronic, grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees from Hamilton, personal fees and non-financial support from Fisher & Paykel, grants from French Ministry of Health, personal fees from Getinge, grants and personal fees from Respinor, grants and non-financial support from Lungpacer. Other authors report no conflict of interest.
